<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052778</url>
  </required_header>
  <id_info>
    <org_study_id>TPU-TAS-120-101</org_study_id>
    <secondary_id>2013-004810-16</secondary_id>
    <nct_id>NCT02052778</nct_id>
  </id_info>
  <brief_title>A Study of TAS-120 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, nonrandomized, Phase 1 dose-escalation, dose-expansion, and Phase 2
      study targeting tumors with FGF/FGFR aberrations. The purpose of the study is to evaluate the
      safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of TAS-120 in patients
      with advanced solid tumors with and without FGF/FGFR-related abnormalities.

      The study will be conducted in 3 parts, (1) Dose escalation to determine the MTD and/ or RP2D
      of TAS-120 in which this part of the study has been completed; (2) Phase 1 expansion to
      further evaluate the safety and efficacy of RP2D of TAS-120 in patients with tumors harboring
      specific FGFR aberrations, specifically in patients with cholangiocarcinoma, gliomas ,
      urothelial carcinomas and any other tumors with FGFR fusion or activating mutation or
      amplification. Up to approximately 185 patients will be enrolled in the phase 1 expansion;
      and (3) Phase 2 study to confirm ORR of TAS-120 in intra-hepatic CCA patients with tumors
      harboring FGFR2 gene fusions. Approx. 100 patients will be enrolled in phase 2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 Dose Escalation Phase 1 Dose Escalation has been completed as of Dec 2017

      Phase 1 Dose Expansion:

      Up to approximately 185 patients will be enrolled among the 8 groups as outlined below:

        -  Group 1- CCA (iCCA or eCCA) with FGFR2 gene fusions.

        -  Group 2- CCA (iCCA or eCCA) with FGFR2 gene fusions that are chemotherapy naive or
           intolerant to first line chemotherapy (i.e., on chemotherapy regimen ≤ 1 cycle).

        -  Group 3 - CCA (iCCA or eCCA) with FGFR2 gene fusions treated with prior FGFR inhibitors.

        -  Group 4 - CCA (iCCA or eCCA) with other FGFR2 abnormalities, ie, gene mutations,
           rearrangements or amplifications.

        -  Group 5 - GBM or grade III glioma (i.e, anaplastic astrocytoma or anaplastic
           oliogodendroglioma) with FGFR gene fusions or activating mutations

        -  Group 6 - Advanced urothelial carcinoma with FGFR3 fusions or FGFR3 activating
           mutations.

        -  Group 7: Basket of tumor types with tumors harboring FGFR2 amplification (≥10 copies).

        -  Group 8 - Basket of tumor types (except CCA, brain tumors and advanced urothelial
           carcinomas) with tumors harboring FGFR gene fusions or activating mutations.

      Phase 2:

      Approximately 100 iCCA patients with confirmed FGFR2 gene fusions will be treated. Patients
      will be centrally screened for FGFR2 gene fusions. This is a Single arm study with the
      primary endpoint of ORR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 - Overall Response Rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>Response assessments will be made based on RECIST guidelines (version 1.1, 2009) for solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Early Progression Rate (EPR) for GBM or grade III glioma</measure>
    <time_frame>12 months</time_frame>
    <description>Response assessments will be made based RANO for brain tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Overall Response Rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>Response assessments will be made based on RECIST guidelines (version 1.1, 2009) for solid tumors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>12 months</time_frame>
    <description>DOR is defined as time from first documentation of response to the first documentation of objective tumor progression or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>12 months</time_frame>
    <description>DCR is defined as proportion of patients with objective evidence of complete response, partial response or stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>PFS is defined as time from the day of first dose to the date of first objectively documented disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO)</measure>
    <time_frame>12 months</time_frame>
    <description>PCR is define as the analysis of EQ-5D and EORTC QLQ-C30 from baseline through end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>OS is defined as date of first dose to death date in the safety population of Phase 1 and safety and efficacy population for phase 2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">371</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <condition>Brain Tumor</condition>
  <condition>Urothelial Cancer</condition>
  <condition>Other Tumor Types With FGFR2 Gene Fusions</condition>
  <condition>Activating Mutations</condition>
  <condition>FGFR2 Amplification</condition>
  <arm_group>
    <arm_group_label>TAS-120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS-120 tablets, oral; 21-day cycle
Dose escalation portion of the study was completed.
Dose expansion- patients with tumors harboring specific FGFR aberrations, specifically in CCA, Brain Tumor , Urotherial carcinoma and any other tumors with FGFR fusion, activating mutation and amplification.
Phase 2- intra-hepatic CCA patients with tumors harboring FGFR2 gene fusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-120</intervention_name>
    <arm_group_label>TAS-120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Has histologically or cytologically confirmed, locally advanced, metastatic cancer meeting
        the following criteria:

        Phase 1 Expansion

          1. Patient has failed all standard therapies or standard therapy does not exist or is not
             tolerated.

          2. Patient has specific FGF/FGFR aberrations

               -  Intrahepatic or extrahepatic cholangiocarcinoma with FGFR2 gene fusions or other
                  FGFR2 abnormalities, i.e., gene mutations (see Appendix A), rearrangements or
                  amplifications

               -  Glioblastoma or grade III glioma (i.e., anaplastic astrocytoma or anaplastic
                  oligodendroglioma) with FGFR gene fusions or activating mutations.

               -  Advanced urothelial carcinoma with FGFR3 fusions or FGFR3 activating mutations

               -  All other tumor types harboring FGF9, FGF19 or FGFR2 amplifications (≥ 10
                  copies), FGFR gene fusions, or FGFR activating mutations

        Phase 2

          1. Patient has histologically or cytologically confirmed, locally advanced, metastatic,
             unresectable iCCA harboring FGFR2 gene fusions based on results from a NGS assay by
             the Sponsor's designated central laboratory

          2. Patient has been treated with and failed at least one prior systemic gemcitabine and
             platinum-based chemotherapy for the advanced disease

          3. Must have documentation of radiographic progression of disease on prior systemic
             therapy

          4. Patient has measurable disease as defined by Response Evaluation Criteria in Solid
             Tumors (RECIST) guidelines (version 1.1, 2009) for advanced solid tumors or RANO
             criteria (2010) for brain tumors.

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          6. Adequate organ function

        Exclusion Criteria:

        A patient will be excluded from this study if any of the following criteria are met:

          1. History and/or current evidence of non-tumor related alteration of calcium-phosphorus
             homeostasis.

          2. History and/or current evidence of clinically significant ectopic
             mineralization/calcification.

          3. History and/or current evidence of clinically significant retinal disorder confirmed
             by retinal examination.

          4. A serious illness or medical condition(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Huang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Taiho Oncology, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jerry Huang, MD</last_name>
    <email>jhuang@taihooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic (AZ)</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF - Helen Diller</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (Jacksonville)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Lynch</last_name>
      <phone>617-643-0815</phone>
      <email>lynch.patricia2@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (MN)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huan, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Jefferson</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenville Health System ITOR</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Hu, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Funda Meric-Bernstam, MD</last_name>
      <phone>713-792-3737</phone>
      <email>Fmeric@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard Bât</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute Goustave-Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rennes, Centre Eugène Marquis</name>
      <address>
        <city>Rennes cedex</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Val D'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona,</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal - Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Boni, MD</last_name>
      <phone>+34 917567825</phone>
      <email>Valentina.Boni@start.stoh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>W1T 7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Huang, MD</last_name>
      <phone>609-250-7208</phone>
      <email>jhuang@taihooncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>FGF</keyword>
  <keyword>FGFR</keyword>
  <keyword>FGFR abnormality</keyword>
  <keyword>TAS-120</keyword>
  <keyword>Dose Escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

